Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) EBIT (2022 - 2025)

Bioregenx's EBIT history spans 4 years, with the latest figure at -$935658.0 for Q4 2025.

  • Quarterly results put EBIT at -$935658.0 for Q4 2025, up 94.89% from a year ago — trailing twelve months through Dec 2025 was -$1.2 million (up 94.54% YoY), and the annual figure for FY2025 was -$1.2 million, up 94.54%.
  • EBIT for Q4 2025 was -$935658.0 at Bioregenx, down from -$8459.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$2191.0 in Q3 2022 to a low of -$18.3 million in Q4 2024.
  • The 4-year median for EBIT is -$202085.0 (2023), against an average of -$1.7 million.
  • The sharpest move saw EBIT plummeted 112567.87% in 2023, then soared 97.42% in 2025.
  • Year by year, EBIT stood at -$5535.0 in 2022, then crashed by 3722.13% to -$211555.0 in 2023, then plummeted by 8558.18% to -$18.3 million in 2024, then surged by 94.89% to -$935658.0 in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$935658.0, -$8459.0, and -$107259.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.